Abstract Number: 2584 • 2014 ACR/ARHP Annual Meeting
Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis
Background/Purpose Smoking has been reported as associated with increase disease activity, more functional impairment, poorer quality of life and more radiographic damages in patients (pts)…Abstract Number: 1522 • 2014 ACR/ARHP Annual Meeting
Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Background/Purpose: Sarilumab, a fully human monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy in the phase 3 part of the RA-MOBILITY study (NCT01061736) in…Abstract Number: 2559 • 2014 ACR/ARHP Annual Meeting
Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders
Background/Purpose Vitamin D plays an important role in the modulation of immune system and epidemiologic data indicate low vitamin D levels in autoimmune diseases such…Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…Abstract Number: 2482 • 2014 ACR/ARHP Annual Meeting
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
Background/Purpose The treatment for Rheumatoid Arthritis (RA) is based on synthetic or biological disease-modifying drugs (DMARDs). Current guidelines recommend biologics in combination with methotrexate as…Abstract Number: 1432 • 2014 ACR/ARHP Annual Meeting
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment: HUR-BIO real life results.Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, which, in many patients, leads…Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…Abstract Number: 1251 • 2014 ACR/ARHP Annual Meeting
Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases
Background/Purpose Anti-TNF-α therapy may be useful in cases of uveitis refractory to standard synthetic immunosuppressive drugs. Infliximab (IFX) and adalimumab (ADA) are the biologic agents…Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting
Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting
Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease
Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT
Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…